Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with ...

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

LOUISVILLE, Ky., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Onco360 ®, the nation’s leading independent specialty pharmacy, has been chosen by Rigel Pharmaceuticals as limited distribution specialty pharmacy ...

Rigel Pharmaceuticals RIGL will release its quarterly earnings report on Tuesday, 2025-08-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Rigel Pharmaceuticals ...

SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ...

Rigel Pharmaceuticals (NASDAQ:RIGL) is gearing up to announce its quarterly earnings on Tuesday, 2025-11-04. Here's a quick overview of what investors should know before the release. Analysts are ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 6: Rigel ...

Rigel Pharmaceuticals reported promising preliminary Q4 and full-year 2023 results, with record-breaking net product sales for TAVALISSE and REZLIDHIA. The company's cash position remains healthy, ...

SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close ...